Exchange: NASDAQ·Updated 07:30 PM EST
SNY logo

SNY Sanofi-Aventis

$46.52
$0.46
(1.00%)
Today
Closed $46.52
$0.00
(0.00%)
After Hours
Reported EarningsOct 30
Mkt Cap$110.88B
Vol4.29M

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines, vaccines franchises, support, and corporate functions 1973 and is headquartered in Paris, France.
69

Bullish Sentiment

How do you feel about SNY?

TheGunnerAB
What are the chances Bloomberg got the rumor wrong and $SNY is actually buying $TGTX or $ABVX and not $INSM? I don't see how they can afford $INSM.
11
TopShelfStock
After-Hours Update: All eyes locked on Sanofi's ($SNY) Q3 print tomorrow morning—the ultimate proxy signal for $NVAX. Algorithmic scanners are tracking their qualitative transcripts for European launch pacing, revenue-recognition windows on today’s $125M cash milestone, and combination pipeline guidance. Smart money ignores retail noise and focuses on pure operating leverage. Cruising this structural turnaround straight up Highway 331. Steady the helm.
10
SGL_FGHI
$SNY acquiring $TGTX for Briumvi’s $1B+ growth engine while getting azer-cel’s Phase 1 progressive MS asset makes financial and strategic sense – as SNY looks to fortify its MS franchise after U.S. regulatory delays on tolebrutinib. Azer-Cel Adds Asymmetric Upside: Because BRIUMVI pays for most of the acquisition price, SNY would effectively acquire azer-cel at a modest net cost. If azer-cel succeeds in progressive MS and reaches $1.5 billion to $3+ billion in peak annual sales in the 2030s, it turns a solid bolt-on deal into a highly accretive home run. Broader Immunology Expansion: Beyond MS, SNY is an immunology giant (led by Dupixent). Axer-cel’s planned expansion into myasthenia gravis, CIDP, and lupus aligns directly with SNY’s core therapeutic areas.
8
BiotechSwings
then the back half of the month Nov 25 $SNY venglustat in type 3 Gaucher, first US shot at the brain side of the disease. Nov 27 BBIO BBP 418 in LGMD, first therapy for that form if it lands. Nov 28 $PYPD DPLEX100 for surgical infections, Saturday date so Friday is the window Nov 30 $VRTX povetacicept in IgAN and Cogent bezuclastinib in GIST, plus $GSK neladalkib still expected in November with no day given
2
BiotechSwings
Thanksgiving week is where it stacks up Nov 25 $SNY venglustat for type 3 Gaucher, Priority Review, LEAP2MONO beat enzyme replacement on the neurological scores and no US therapy touches that side yet Nov 27 $BBIO BBP 418 for LGMD2I R9, Priority Review, FORTIFY hit everything at the 12 month interim Nov 27 $GSK neladalkib in ALK positive lung cancer after a TKI, Priority Review and built to reach the brain Nov 28 $PYPD D PLEX100 for surgical site infections, SHIELD II cut infections 60% vs standard care Nov 28 is a Saturday and markets are closed Thanksgiving Thursday, so Friday does double duty that week imo
1
TopShelfStock
Pre-Market Update: Sanofi ($SNY) officially smashes Q3 expectations this morning with €14.44B in net sales and an upgraded full-year corporate guidance model. The algorithmic proxy signal is completely green. While the retail boards panic over lagging index noise, institutional fund models are tracking this massive global infrastructure scaling. Sanofi's upgraded commercial footprint directly accelerates the structural monetization and royalty velocity of the Matrix-M adjuvant pipeline. Market makers are shuffling inventory brackets to support the rising technical floor ahead of the Nov 5 print. True enterprise valuation is built on raw partner-led execution data, and the long-term cruise control is set straight up Highway 331. Steady the helm. NVAX SNY
1
notreload_ai
Jefferies: $SNY has >€25B for deals. Buying $INSM at a 30% premium (~€31B) is possible. M&A is key before Dupixent patent expiry. Buy rating on $SNY.
BiotechSwings
9 days out on $SNY and nobody is treating it like a first Nov 25 PDUFA, Priority Review venglustat for type 3 Gaucher, oral and built to get into the brain LEAP2MONO beat enzyme replacement on both neurological primaries, p equals 0.007, and matched it on spleen, liver and hemoglobin no approved US therapy targets the neurological side of GD3. closed 48.39 today, basically flat while the sector got hit imo
MarketKingdoms
$SNY Q3 '26 sales reached €14.4B (+14.3% YoY; +12% underlying), led by Dupixent at €5.7B and 1.5M+ patients. Pharma launches grew 31%, rare diseases 12.6%. Gross margin expanded 2.1pp, operating margin 1.9pp; business EPS +19.6%. FY26 guidance raised to 13–15% sales growth and 15–17% EPS growth. Catalysts in play - Dupixent €25B sales target for 2030 reaffirmed. - Regeneron alliance expands into 4 next-gen immunology assets. - Anti-IL-13 registrational studies targeted late 2027/early 2028. - R&D reset: AI, China partnerships, 12–15 first-in-human studies yearly. - New launches now account for 15% of sales. Risks to watch - 2027 pricing expected slightly negative; Q3 gross-to-net benefit partly one-off. - Cheplapharm/Medley disposals reduce 2027 sales by ~€1.3B. - €500M Regeneron reimbursement headwind in H2 '26. - Amlitelimab and itepekimab stopped; frexalimab Phase III extended. - Dupixent patent expiry post-2030 raises replacement risk. - AMVUTTRA royalties face 2027 uncertainty.
TopShelfStock
Pre-Market Update: Sanofi ($SNY) officially smashes Q3 expectations this morning with €14.44B in net sales and an upgraded full-year corporate guidance model. The algorithmic proxy signal is completely green. While the retail boards panic over lagging index noise, institutional fund models are tracking this massive global infrastructure scaling. Sanofi's upgraded commercial footprint directly accelerates the structural monetization and royalty velocity of the Matrix-M adjuvant pipeline. Market makers are shuffling inventory brackets to support the rising technical floor ahead of the Nov 5 print. True enterprise valuation is built on raw partner-led execution data, and the long-term cruise control is set straight up Highway 331. Steady the helm. NVAX SNY
StocktwitsEarnings
$SNY Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $2.01 up 17.54% YoY • Reported revenue of $17.25B up 11.64% YoY • Sanofi upgraded FY 2026 guidance: sales are expected to grow by a low-teens percentage at CER, and business EPS at CER is expected to grow by a mid-teens percentage.

Advertisement|Remove ads.